


## UbcH5c-IN-1

Cat. No.:	HY-103046
CAS No.:	2123480-72-6
Molecular Formula:	C <sub>22</sub> H <sub>21</sub> BrO <sub>3</sub>
Molecular Weight:	413.3
Target:	E1/E2/E3 Enzyme
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	UbcH5c-IN-1 (compound 6d) is a potent and selective small-molecule inhibitor of Ubiquitin-conjugating enzyme UbcH5c, with a K <sub>d</sub> of 283 nM for E2 UbcH5c-IN-1 by covalent binding with Cys85. A promising lead compound for the development of new antirheumatoid arthritis (RA) agent <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	Kd: 283 nM (E2 UbcH5c) <sup>[1]</sup> .								
<b>In Vivo</b>	<p>UbcH5c-IN-1 (compound 6d) (5 and 20 mg/kg, p.o., daily, 10-20 days) treatment in Freund's adjuvant (CFA)-induced adjuvant arthritis (AA) rat model results in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Freund's adjuvant (CFA)-induced adjuvant arthritis (AA) rat model<sup>[1]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>5 and 20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration daily between day 10-20 postimmunization.</td> </tr> <tr> <td>Result:</td> <td>Resulted in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group.</td> </tr> </table>	Animal Model:	Freund's adjuvant (CFA)-induced adjuvant arthritis (AA) rat model <sup>[1]</sup> .	Dosage:	5 and 20 mg/kg	Administration:	Oral administration daily between day 10-20 postimmunization.	Result:	Resulted in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group.
Animal Model:	Freund's adjuvant (CFA)-induced adjuvant arthritis (AA) rat model <sup>[1]</sup> .								
Dosage:	5 and 20 mg/kg								
Administration:	Oral administration daily between day 10-20 postimmunization.								
Result:	Resulted in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group.								

### REFERENCES

[1]. Chen H, et al. Discovery of Potent Small-Molecule Inhibitors of Ubiquitin-Conjugating Enzyme UbcH5c from  $\alpha$ -Santonin Derivatives. J Med Chem. 2017 Aug 24;60(16):6828-6852.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA